The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance

Waseem Kaialy, Hassan Larhrib, Gary P. Martin, Ali Nokhodchi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures. Methods Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using antisolvent precipitation technique. Obtained crystals were sieved to separate 63-90 μm size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC. Results At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised ß-lactose showed different anomers compared to commercial lactose (a-lactose monohydrate). Crystallised a- mannitol showed different polymorphic form compared to commercial mannitol (ß-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to a-mannitol, a- lactose monohydrate, ß-lactose, 5a-/3ß-lactose and 4a-/1ß-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers. Conclusion The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.

Original languageEnglish
Pages (from-to)2139-2156
Number of pages18
JournalPharmaceutical Research
Volume29
Issue number8
Early online date5 Apr 2012
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Dry Powder Inhalers
Mannitol
Lactose
Powders
Crystallization
Crystals
Concurrent engineering
Albuterol

Cite this

Kaialy, Waseem ; Larhrib, Hassan ; Martin, Gary P. ; Nokhodchi, Ali. / The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance. In: Pharmaceutical Research. 2012 ; Vol. 29, No. 8. pp. 2139-2156.
@article{6d771ec34ac141a8995829b18edd789f,
title = "The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance",
abstract = "Purpose To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures. Methods Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using antisolvent precipitation technique. Obtained crystals were sieved to separate 63-90 μm size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC. Results At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised {\ss}-lactose showed different anomers compared to commercial lactose (a-lactose monohydrate). Crystallised a- mannitol showed different polymorphic form compared to commercial mannitol ({\ss}-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to a-mannitol, a- lactose monohydrate, {\ss}-lactose, 5a-/3{\ss}-lactose and 4a-/1{\ss}-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers. Conclusion The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.",
keywords = "Fine carrier, In vitro aerosolisation, Mannitol: Lactose ratio, Roughness, Salbutamol sulphate, Shape, Size, Solid state",
author = "Waseem Kaialy and Hassan Larhrib and Martin, {Gary P.} and Ali Nokhodchi",
year = "2012",
month = "8",
doi = "10.1007/s11095-012-0743-3",
language = "English",
volume = "29",
pages = "2139--2156",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "8",

}

The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance. / Kaialy, Waseem; Larhrib, Hassan; Martin, Gary P.; Nokhodchi, Ali.

In: Pharmaceutical Research, Vol. 29, No. 8, 08.2012, p. 2139-2156.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance

AU - Kaialy, Waseem

AU - Larhrib, Hassan

AU - Martin, Gary P.

AU - Nokhodchi, Ali

PY - 2012/8

Y1 - 2012/8

N2 - Purpose To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures. Methods Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using antisolvent precipitation technique. Obtained crystals were sieved to separate 63-90 μm size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC. Results At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised ß-lactose showed different anomers compared to commercial lactose (a-lactose monohydrate). Crystallised a- mannitol showed different polymorphic form compared to commercial mannitol (ß-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to a-mannitol, a- lactose monohydrate, ß-lactose, 5a-/3ß-lactose and 4a-/1ß-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers. Conclusion The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.

AB - Purpose To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures. Methods Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using antisolvent precipitation technique. Obtained crystals were sieved to separate 63-90 μm size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC. Results At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised ß-lactose showed different anomers compared to commercial lactose (a-lactose monohydrate). Crystallised a- mannitol showed different polymorphic form compared to commercial mannitol (ß-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to a-mannitol, a- lactose monohydrate, ß-lactose, 5a-/3ß-lactose and 4a-/1ß-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers. Conclusion The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.

KW - Fine carrier

KW - In vitro aerosolisation

KW - Mannitol: Lactose ratio

KW - Roughness

KW - Salbutamol sulphate

KW - Shape

KW - Size

KW - Solid state

UR - http://www.scopus.com/inward/record.url?scp=84864490841&partnerID=8YFLogxK

U2 - 10.1007/s11095-012-0743-3

DO - 10.1007/s11095-012-0743-3

M3 - Article

VL - 29

SP - 2139

EP - 2156

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 8

ER -